Lilly, FDA Discussing Insulin GMP Upgrades To Avoid Supply Restrictions
Executive Summary
Lilly is in discussions with FDA over approaches to upgrade its insulin manufacturing processes without causing supply issues
You may also be interested in...
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Lilly GMP Strategy: Avoid Consent Degree With Open Communication At FDA
Lilly's ongoing, "open" communication with FDA over good manufacturing practices should help avoid a consent decree, CFO Charles Golden said during the Bear Stearns healthcare conference in New York Sept. 19